证券代码：000566 证券简称：海南海药 公告编号：2023-065 海南海药股份有限公司 2023 年第四次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、特别提示： 1、本次股东大会无否决议案的情形； 2、本次股东大会不涉及变更前次股东大会决议的情形。 二、会议召开的情况 （1）通过深圳证券交易所交易系统进行网络投票的时间为：2023年11月15日 9：15～9：25，9：30～11：30和13：00～15：00； （2）通过深圳证券交易所互联网投票系统投票的时间为：2023年11月15日9:15～ 15:00期间的任意时间。 2、召开地点：海南省海口市秀英区南海大道 192 号海药工业园公司会议室 3、召开方式：采用现场表决与网络投票相结合的方式召开 4、召集人：公司第十一届董事会 5、会议主持人：董事长王建平 6、公司已于 2023 年 10 月 28 日在巨潮资讯网（http://www.cninfo.com.cn）刊登 了《关于召开 2023 年第四次临时股东大会的通知》，本次股东大会的内容及大会召集、 召开方式、程序均 ...

Financial Performance - The company's revenue for Q3 2023 was ¥293,077,257.52, a decrease of 28.36% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥34,092,369.05, representing a 29.63% increase in losses year-over-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥54,117,396.69, a decrease of 27.44% compared to the previous year[5]. - Total operating revenue for the current period is ¥1,252,651,828.58, a decrease of 15.0% from ¥1,474,222,452.43 in the previous period[25]. - Net profit for the current period is -¥39,388,820.44, compared to -¥49,809,751.72 in the previous period, showing an improvement of 20.0%[26]. Cash Flow - The operating cash flow net amount for the year-to-date was ¥12,457,178.90, down 89.82% from the previous year[5]. - Net cash flow from operating activities dropped by 89.82% to CNY 12,457,178.90, mainly due to extended settlement periods and reduced tax refunds[10]. - Cash flow from operating activities generated a net amount of ¥12,457,178.90, a significant decrease from ¥122,311,458.09 in the previous period[28]. - The net cash flow from investing activities was CNY -72,523,551.54, a significant decrease compared to CNY 176,280,287.72 in the previous year[10]. - The net cash flow from financing activities improved by 83.95% to CNY -99,694,026.67, primarily due to reduced repayments of borrowings[10]. Assets and Liabilities - Total assets at the end of the reporting period were ¥7,296,321,662.90, a decrease of 0.94% from the end of the previous year[5]. - The company's cash and cash equivalents decreased by 40.87% to ¥233,300,040.73 due to fixed asset and R&D investments[8]. - The company's current liabilities increased to CNY 3,627,038,505.67 from CNY 4,002,711,952.06 at the beginning of the year, indicating a significant rise in short-term obligations[23]. - The total non-current liabilities rose to CNY 1,375,365,615.44, compared to CNY 1,025,553,677.52 at the start of the year, reflecting an increase in long-term financial commitments[23]. Inventory and Receivables - Inventory increased by 41.91% to ¥393,218,354.56, attributed to reasonable production reserves according to sales plans[8]. - The company reported a 97.15% increase in receivables financing to ¥47,594,591.31, mainly due to an increase in bank acceptance bills received[8]. - The accounts receivable increased to CNY 350,934,633.24 from CNY 326,448,446.69, showing a growth in credit sales[22]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 52,365[11]. - The largest shareholder, Hainan Huadong Industrial, holds 22.89% of shares, totaling 296,989,889 shares, with 148,494,944 shares pledged[11]. Legal and Regulatory Issues - The company is currently involved in a legal dispute regarding a contract with Yancheng Fengkang Fund, which may impact future financial performance[19]. - The company has been under investigation by the China Securities Regulatory Commission for alleged information disclosure violations, which could affect its market reputation[20]. Other Financial Metrics - The company's weighted average return on net assets was -1.59%, a decrease of 0.70% compared to the previous year[5]. - Basic earnings per share for the current period is -0.0189, an improvement from -0.0520 in the previous period[26]. - The company recorded a significant increase in credit impairment losses to ¥68,681,199.06 from ¥9,089,213.52 in the previous period[25].

特此说明。 独立董事签字：魏玉林 张强 胡秀群 2023 年 10 月 27 日 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司独立 董事管理办法》等法律法规规范性文件，和《公司章程》的有关规定，我们作为 海南海药股份有限公司（以下简称"公司"）第十一届董事会独立董事，本着认 真、负责、独立判断的态度，核查了相关资料，经审慎分析，现就公司第十一届 董事会第四次会议审议的《关于拟变更会计师事务所的议案》发表如下独立意见： 鉴于原审计机构大华会计师事务所（特殊普通合伙）已连续多年为公司提供 审计服务，综合考虑公司整体审计工作的需要，为保证上市公司审计的独立性、 客观性、公允性，公司本次拟变更并聘请中审众环会计师事务所（特殊普通合伙） （以下简称"中审众环"）为公司 2023 年度财务审计和内部控制审计机构。经对 中审众环具体情况进行认真核查，我们认为其具有多年为上市公司提供审计服务 的经验与能力，具备从事证券期货相关业务审计资格，能够满足公司 2023 年度 财务审计和内部控制审计工作的要求。公司本次拟变更会计师事务所不存在损害 公司及股东利益，尤其是中小股东利益的情形。因此，我们同意聘任中审 ...

本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 海南海药股份有限公司（以下简称"公司"或"海南海药"）第十一届董事 会第四次会议于 2023 年 10 月 27 日以通讯方式召开。本次会议于 2023 年 10 月 24 日以电子邮件等方式送达了会议通知及文件。会议应到董事 9 人，实到董事 9 人，会议的召开符合《公司法》和《公司章程》有关规定。经与会董事认真审议， 表决通过了如下议案： 一、 审议通过了《 2023 年第三季度报告的议案》 具体内容详见同日刊载于巨潮资讯网（http//www.cninfo.com.cn）的《海 南海药股份有限公司 2023 年第三季度报告》。 表决结果：9 票同意，0 票反对，0 票弃权 证券代码：000566 证券简称：海南海药 公告编号：2023-061 海南海药股份有限公司 第十一届董事会第四次会议决议公告 此议案须提交 2023 年第四次临时股东大会审议。 三、审议通过了《关于召开 2023 年第四次临时股东大会的议案》 1 具体内容详见同日于巨潮资讯网（http//www.cninfo.com.cn）刊载的《关 于 ...

证券代码：000566 证券简称：海南海药 公告编号：2023-062 海南海药股份有限公司 关于召开 2023 年第四次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：本次股东大会为 2023 年第四次临时股东大会 2、股东大会的召集人：公司第十一届董事会。公司第十一届董事会第四次会议于 2023年10月27日审议通过了《关于召开 2023 年第四次临时股东大会的议案》。 3、会议召开的合法、合规性：本次股东大会的召开程序符合有关法律、行政法规、 部门规章、规范性文件和《公司章程》等的规定。 4、会议召开的日期、时间： 现场会议召开时间：2023年11月15日下午15：00 网络投票时间：2023年11月15日 （1）通过深圳证券交易所交易系统进行网络投票的时间为：2023年11月15日 9：15～9：25，9：30～11：30和13：00～15：00； （2）通过深圳证券交易所互联网投票系统投票的时间为：2023年11月15日9:15～ 15:00期间的任意时间。 5、会议的召开方式：本次股东大 ...

证券代码：000566 证券简称：海南海药 公告编号：2023-063 海南海药股份有限公司 关于拟变更会计师事务所的公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别提示： 1、拟聘任会计师事务所：中审众环会计师事务所（特殊普通合伙）（以下 简称"中审众环"）；原聘任会计师事务所：大华会计师事务所（特殊普通合 伙）（以下简称"大华事务所"）。 2、变更会计师事务所原因：鉴于原审计机构大华事务所已连续多年为海南 海药股份有限公司（以下简称"公司"或"海南海药"）提供审计服务，综合考 虑公司整体审计工作的需要，为保证上市公司审计的独立性、客观性、公允 性，经综合评估考虑，拟变更并聘任中审众环为公司 2023 年度财务审计和内 部控制审计机构，聘任期为一年。 3、公司董事会审计委员会、独立董事、董事会对本次拟变更会计师事务所 均无异议，本事项尚须提交公司股东大会审议。 一、拟聘任会计师事务所的基本情况 （一）机构信息 1、基本信息 （1）机构名称：中审众环会计师事务所（特殊普通合伙） （2）成立日期：中审众环始创于 1987 年，是全国首批取得国家批准具有从 ...

证券代码：000566 证券简称：海南海药 公告编号：2023-060 海南海药股份有限公司 关于公司及原实际控制人收到中国证券监督管理委员会 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 海南海药股份有限公司（以下简称"公司"）及公司原实际控制人刘悉承先 生于 2023 年9月28日收到中国证券监督管理委员会（以下简称"中国证监会"） 的《立案告知书》（证监立案字 2023029007 号）、（证监立案字 2023029008 号）， 因涉嫌信息披露违法违规，根据《中华人民共和国证券法》《中华人民共和国行 政处罚法》等法律法规，中国证监会决定对公司及原实际控制人、公司副董事长 刘悉承先生立案。公司及原实际控制人刘悉承先生将积极配合中国证监会的相关 工作，并严格按照监管要求履行信息披露义务。 上述立案调查内容发生于 2020 年之前，是现控股股东海南华同实业有限公 司收购公司之前事项，属于历史遗留问题。相关事项多数已解决，尚未解决事项 已有解决方案，正在执行。 1 目前公司经营情况正常，公司将持续关注上述事项的进展情况，并严格按照 监管要求履行信息披露义务。公 ...

证券代码：000566 证券简称：海南海药 公告编号：2023-058 海南海药股份有限公司 关于收到一类新药派恩加滨片 I 期临床试验总结报告的公告 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 海南海药股份有限公司（以下简称"公司"）全资子公司海口市制药厂有限 公司与中国科学院上海药物研究所联合研究开发的国家一类新药派恩加滨项目， 于近日收到 I 期临床试验总结报告。 派恩加滨属于化药 1.1 类新药，为新型靶向抗癫痫药物，新一代 KCNQ 钾通 道激动剂，目前全球尚无上市品种，本品可用于难治性癫痫的治疗，主要情况如 下： 一、新药基本信息 药物名称：派恩加滨片 注册分类：化学药品第 1 类 剂型：片剂 适应症：暂定为其他抗癫痫药物不能控制或不能耐受的部分性癫痫 临床批件号：2018L03179，2018L03180 研究内容：单次给药、多次给药安全性、耐受性及药代动力学 研究机构：复旦大学附属华山医院 二、I 期临床研究情况 派恩加滨片 Ia 期研究由低到高依次评估各剂量组受试者单剂口服研究药物 后的耐受性、安全性及药代动力学特征，本次研究数据表明派恩加 ...

海南海药股份有限公司 关于头孢克洛胶囊通过仿制药质量和疗效一致性评价的公告 证券代码：000566 证券简称：海南海药 公告编号：2023-059 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 海南海药股份有限公司（以下简称"公司"或"海南海药"）全资子公司海 口市制药厂有限公司（以下简称"海口市制药厂"）于近日获得国家药品监督管 理局核准签发的化学药品"头孢克洛胶囊"的《药品补充申请批准通知书》。现 将相关情况公告如下： 剂型：胶囊剂 规格：0.25g 申请事项：药品补充申请（一致性评价) 注册分类：化学药品 受理号：CYHB2250363 上市许可持有人：海口市制药厂有限公司 审批结论：经审查，本品通过仿制药质量和疗效一致性评价。 2. 药品的其他相关情况 头孢克洛胶囊为第二代口服头孢菌素类抗生素，其作用机理与其他头孢菌素 相同，主要通过抑制细胞壁的合成起到杀菌作用。该药品适用于敏感菌株引起的 中耳炎、下呼吸道感染（包括肺炎）、咽炎和扁桃体炎、尿路感染、皮肤和皮肤 软组织感染等，具有高效、口服吸收好，组织分布广、不良反应少且轻微等特点。 一、 药品基本情况 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 959,574,571.06, a decrease of 9.91% compared to CNY 1,065,134,639.52 in the same period last year[23]. - The net profit attributable to shareholders was CNY 9,546,078.21, a significant improvement from a loss of CNY 18,989,077.33 in the previous year[23]. - The net cash flow from operating activities decreased by 71.72% to CNY 18,501,155.36 from CNY 65,420,601.39 in the same period last year[23]. - The basic earnings per share increased to CNY 0.0074 from a loss of CNY 0.0146 in the previous year[23]. - The company's total revenue for the reporting period was CNY 959,574,571.06, representing a decrease of 9.91% compared to CNY 1,065,134,639.52 in the previous year[61]. - The pharmaceutical segment accounted for 89.80% of total revenue, with a revenue of CNY 861,707,857.17, down 7.84% from CNY 934,977,828.85[62]. - The revenue from medical devices plummeted by 98.01%, falling to CNY 786,136.77 from CNY 39,546,067.01 in the previous year[62]. - The revenue from the gastrointestinal product "肠胃康" increased by 45.82%, reaching CNY 134,950,876.21, compared to CNY 92,545,013.07 in the previous year[62]. - The revenue from the cephalosporin series was ¥224,594,230, with a gross profit margin of 67.34%, showing an 8.56% increase in revenue year-on-year[63]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 7,754,357,617.56, reflecting a growth of 5.28% from CNY 7,365,442,827.12 at the end of the previous year[23]. - The net assets attributable to shareholders increased by 0.53% to CNY 2,176,321,622.12 from CNY 2,164,791,389.86 at the end of the previous year[23]. - The company's net cash and cash equivalents decreased by CNY 231,100,175.12, a decline of CNY 366,054,496.75 compared to the previous year[61]. - The company's short-term borrowings increased to ¥2,236,389,370, accounting for 28.84% of total liabilities[67]. - The company reported an investment loss of ¥12,375,570.22 from joint ventures during the reporting period[66]. Research and Development - The company reported a significant increase in R&D investment, totaling CNY 126,486,911.31, which is a 77.99% increase compared to CNY 71,063,970.91 from the previous year[61]. - The R&D work has accelerated for innovative drugs, with a focus on applications in infection, oncology, cardiovascular, and central nervous system diseases[35]. - The company has established new research institutes, including an innovative drug research institute and a traditional Chinese medicine research institute, to enhance R&D capabilities[31]. - The company is focusing on therapeutic areas such as anti-infection, neuropsychiatric, digestive, cardiovascular, and oncology in its R&D pipeline[52]. - The company has established four research institutes to drive the transformation from generic drugs to innovative drug development, enhancing its core technology system[86]. Market Strategy and Operations - The company is actively exploring new sales models and enhancing cooperation with leading domestic chains to expand market reach[35]. - The company has implemented a refined marketing strategy to improve terminal control capabilities and boost sales[35]. - The company has launched a "6523 product mix" strategy, targeting 6 types of formulations, 5 types of APIs, 2 types of intermediates, and 3 types of traditional Chinese medicine products[35]. - The company is focusing on enhancing its supply chain resources and has implemented a refined management model to improve overall operational efficiency[38]. - The company is committed to improving its R&D capabilities and product offerings to meet market demands[53]. Environmental Compliance - The company plans to maintain strict compliance with national safety and environmental regulations, ensuring that all production bases meet environmental standards[86]. - The wastewater treatment standards followed by Hainan Haiyao Co., Ltd. comply with the "Water Pollution Prevention and Control Law of the People's Republic of China" and the "Biological Engineering Pharmaceutical Industry Water Pollutant Discharge Standards" (GB 21907-2008)[101]. - The company has implemented continuous technological upgrades to strengthen energy management and pollution control, aiming for sustainable green development[86]. - The company reported a total wastewater discharge of 0.6078 tons/year with a COD concentration of 20 mg/L, meeting the secondary standards for pollutant discharge[110]. - The company has established a comprehensive waste management system to ensure compliance with environmental standards and regulations[111]. Legal and Regulatory Matters - The company is involved in multiple lawsuits, including a claim for 60 million yuan plus interest from Chongqing Jinsai, with a current interest rate of 4.35%[132]. - The company has been recognized for its social responsibility efforts, including community training projects and employment assistance in Xili Village, which has received multiple accolades[122]. - The ongoing litigation and recovery efforts are critical components of Hainan Haiyao's risk management strategy[135]. - The company is focusing on debt recovery through legal channels, indicating a strategic approach to managing financial liabilities[134]. - The company has paid a total of RMB 134.92 million as part of a repayment agreement by the end of July 2023[136]. Shareholder Information - The largest shareholder, Hainan Huatong Industrial Co., Ltd., holds 22.89% of the total shares, amounting to 296,989,889 shares[187]. - The second-largest shareholder, Shenzhen Nanfang Tongzheng Investment Co., Ltd., holds 10.28% of the total shares, amounting to 133,346,318 shares[187]. - The company reported a total of 52,830 common shareholders at the end of the reporting period[187]. - The report confirms that there are no related party transactions among the top shareholders[187]. - The company has not reported any new strategies or market expansions in the current reporting period[184].